Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Rafael Ríos-Tamayo, Agustín Martín-García, Carolina Alarcón-Payer, Dolores Sánchez-Rodríguez, Ana María del Valle Díaz de la Guardia, Carlos Gustavo García Collado, Alberto Jiménez Morales, Manuel Jurado Chacón & José Cabeza Barrera. (2017) Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Design, Development and Therapy 11, pages 2399-2408.
Read now
Read now
Alessandro Canella, Sean W. Harshman, Hanna S. Radomska, Michael A. Freitas & Flavia Pichiorri. (2016) The potential diagnostic power of extracellular vesicle analysis for multiple myeloma. Expert Review of Molecular Diagnostics 16:3, pages 277-284.
Read now
Read now
Paul G Richardson, Jacob P Laubach, Sagar Lonial, Philippe Moreau, Sung-Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksac, Melissa Alsina & Jesús F San-Miguel. (2015) Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Review of Anticancer Therapy 15:7, pages 737-748.
Read now
Read now
Articles from other publishers (16)
Beata Donarska, Adrianna Sławińska-Brych, Magdalena Mizerska-Kowalska, Barbara Zdzisińska, Wojciech Płaziński & Krzysztof Z. Łączkowski. (2023) Thalidomide derivatives as nanomolar human neutrophil elastase inhibitors: Rational design, synthesis, antiproliferative activity and mechanism of action. Bioorganic Chemistry 138, pages 106608.
Crossref
Crossref
Anas Ramadan Kotb, Dina A. Bakhotmah, Abdallah E. Abdallah, Hazem Elkady, Mohammed S. Taghour, Ibrahim. H. Eissa & Mohamed Ayman El-Zahabi. (2022) Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC Advances 12:52, pages 33525-33539.
Crossref
Crossref
Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu & Keshu Zhou. (2022) Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Frontiers in Immunology 13.
Crossref
Crossref
Meng-Yan Deng, Khalil Ali Ahmad, Qiao-Qiao Han, Zi-Ying Wang, Rana Muhammad Shoaib, Xin-Yan Li & Yong-Xiang Wang. (2021) Thalidomide alleviates neuropathic pain through microglial IL-10/β-endorphin signaling pathway. Biochemical Pharmacology 192, pages 114727.
Crossref
Crossref
Maria Antonietta Casu, Ignazia Mocci, Raffaella Isola, Augusta Pisanu, Laura Boi, Giovanna Mulas, Nigel H. Greig, Maria Dolores Setzu & Anna R. Carta. (2020) Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease. Frontiers in Aging Neuroscience 12.
Crossref
Crossref
Pedro Mogollón, Andrea Díaz-Tejedor, Esperanza M. Algarín, Teresa Paíno, Mercedes Garayoa & Enrique M. Ocio. (2019) Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells 8:11, pages 1432.
Crossref
Crossref
Hye‑Rim Won, Dong Hoon Lee, Soo‑Keun Yeon, Hyun‑Wook Ryu, Go Woon Kim & So Hee Kwon. (2019) HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. International Journal of Oncology.
Crossref
Crossref
Pawel Robak, Izabela Drozdz, Janusz Szemraj & Tadeusz Robak. (2018) Drug resistance in multiple myeloma. Cancer Treatment Reviews 70, pages 199-208.
Crossref
Crossref
Alicia M Zukas & David Schiff. (2018) Neurological complications of new chemotherapy agents. Neuro-Oncology 20:1, pages 24-36.
Crossref
Crossref
Patrick R. Hagner, Hsiling Chiu, Maria Ortiz, Benedetta Apollonio, Maria Wang, Suzana Couto, Michelle F. Waldman, Erin Flynt, Alan G. Ramsay, Matthew Trotter, Anita K. Gandhi, Rajesh Chopra & Anjan Thakurta. (2017) Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. British Journal of Haematology 179:3, pages 399-409.
Crossref
Crossref
Francesco Di Raimondo & Concetta Conticello. (2017) Pomalidomide: when expectations are understated. Future Oncology 13:5s, pages 1-2.
Crossref
Crossref
R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong, A Oriol, J Minarik, L Pour, M A Dimopoulos, V Maisnar, D Rossi, H Kasparu, J Van Droogenbroeck, D B Yehuda, I Hardan, M Jenner, M Calbecka, M Dávid, J de la Rubia, J Drach, Z Gasztonyi, S Górnik, X Leleu, M Munder, M Offidani, N Zojer, K Rajangam, Y-L Chang, J F San-Miguel & H Ludwig. (2016) A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31:1, pages 107-114.
Crossref
Crossref
Shaunna L. Beedie, Holly M. Rore, Shelby Barnett, Cindy H. Chau, Weiming Luo, Nigel H. Greig, William D. Figg & Neil Vargesson. (2016)
In vivo
screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
. Oncotarget 7:22, pages 33237-33245.
Crossref
Crossref
Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama K. Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel & Antonia Lopez-Girona. (2016) Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. British Journal of Haematology 172:6, pages 889-901.
Crossref
Crossref
K.M. Kortüm, Y.X. Zhu, C.X. Shi, P. Jedlowski & A.K. Stewart. (2015) Cereblon binding molecules in multiple myeloma. Blood Reviews 29:5, pages 329-334.
Crossref
Crossref
Klaus Podar. (2015) Toward optimizing pomalidomide therapy in MM patients. Blood 125:26, pages 3968-3969.
Crossref
Crossref